Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.
The following is a summary of "Quality of life in idiopathic pulmonary fibrosis in Latin American countries," published in ...
Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...
The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...
The UK IPF Registry has provided new insights into the evolving landscape of idiopathic pulmonary fibrosis management.
Hosted on MSN5h
Pliant Therapeutics Reports Q4 2024 Results and UpdatesPliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...
News Medical on MSN3d
Health organizations collaborate to address idiopathic pulmonary fibrosis on Rare Disease Day 2025The American College of Chest Physicians (CHEST), the PF Warriors, the Rare Disease Diversity Coalition (RDDC)-a program at the Black Woman's Health Imperative-and the National Association of ...
The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback